Videos

Expert perspectives on the typical patient workup that occurs in oncology practice to identify cardiovascular risk.

Cardiologist Anees A. Daud, MD, elucidates examinations and tests that help to identify cardiovascular risk in practice.

Medical oncologist Joelle Hamilton, MD, reflects on the prevalence of cardiovascular risk while managing prostate cancer in patients.

Direct insight from a cardiologist on the advent of cardiovascular risk when treating a patient for prostate cancer.

“We need to pursue further education in the field and reach out to every community practice and make them understand that we do now have the guidelines in place, the reimbursement in place, and cost is going down for actually adding system-wide germline and somatic testing for these patients,” says Eleni Efstathiou, MD, PhD.

“There are some situations where I do place stents, but I am really trying to limit [my] amount of stent usage,” says Christopher Allam, MD.

"The majority of my talk focused on describing differences in cancer-specific [survival] as well as overall survival," says Christine Ibilibor, MD.

The toxicity profile was consistent with the first interim analysis of the phase 3 MAGNITUDE study with no new safety signals observed.

"These numbers compared favorably to [CheckMate-214], indicating the value of having a regimen where there was a defined treatment endpoint," says Michael B. Atkins, MD.

“We need to leverage these great platforms to put out high-quality information with experts that people can listen to from home or on the go and get the information that they need,” says Stacy Loeb, MD, MSc.

The updated data sustained the previous radiographic progression-free survival benefit observed with the niraparib combination and showed that the combination also met several secondary end points.

"[This is] a group of patients that there are few treatments available for, and we're excited about the data," says Daniel P. Petrylak, MD.

"Looking at the effect of the darolutamide on docetaxel, we didn't see much of a difference in dose reduction, dose modification, or dose hold for docetaxel, telling you that darolutamide didn't really affect the dosing of docetaxel," says Arash Rezazadah Kalebasty, MD.

"We're trying to understand where these new therapeutic agents might fit into our paradigms of care," says John L. Gore, MD, MS.

"This trial did not require a biomarker for entry in, so patients were treated with combination therapy or standard care, which would have been the abiraterone alone, to see if there was a benefit," says Michael S. Cookson, MD, MMHC.

“The effect size for adjuvant nivolumab versus placebo across primary, secondary, and exploratory endpoints is all remarkably stable,” says Matthew D. Galsky, MD.

"The median survival of the combination arm was 16.1 months versus 13.4 months in the standard chemo arm," says Enrique Grande, MD.

“There are a number of trials that we're interested in to develop potentially combining chemotherapy and neoadjuvant immunotherapy,” says Joshua J. Meeks, MD, PhD.

"The MMAI model had significantly improved accuracy and prognostication to discriminate which patients would develop distant metastasis or die from prostate cancer," says Daniel E. Spratt, MD.

Expert perspectives on strategies to optimize communication, both between healthcare professionals and with patients who present with prostate cancer.

Cardiologist Anees A. Daud, MD, breaks down the typical patient with prostate cancer seen at his practice.

Urologist David Morris, MD, FACS, defines the typical patient with prostate cancer treated at his practice.

Oncologist Joelle Hamilton, MD, shares her perspective on the typical patient with prostate cancer seen at her institution.

Centering focus on a patient case of cardiovascular risk and prostate cancer, experts share their perspective on management strategies.

Comprehensive insight regarding strategies to mitigate cardiovascular risk in patients on therapy for prostate cancer.

Shared insight on a timeline of clinical studies contextualizing cardiovascular disease in the setting of prostate cancer management.

“I would ask the practicing urologist to keep an open mind and not be dogmatic about how they've practiced in the past, and to consider the multiple lines of both indirect and direct evidence that exist,” says Surena F. Matin, MD.

Expert perspectives on the risk of cardiovascular disease as it exists in the context of androgen deprivation therapy (ADT) and prostate cancer.

"We found that if the patient has normal IsoPSA, he has only 1% of risk of developing clinically significant prostate cancer in a median follow-up time of 18 months," says Nour Abdallah, MD.

“Same-day discharge after partial nephrectomy in properly selected patients is safe and cost effective for both patients and the health system,” says Andrew Wood, MD.